Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xortx Therapeutics Inc (XRTX)

Xortx Therapeutics Inc (XRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,143
  • Shares Outstanding, K 6,962
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,310 K
  • EBIT $ -3 M
  • EBITDA $ -3 M
  • 60-Month Beta 0.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.47
  • Most Recent Earnings $-0.13 on 11/14/25
  • Next Earnings Date 03/24/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5100 +17.63%
on 12/22/25
0.6201 -3.26%
on 12/17/25
-0.0101 (-1.66%)
since 12/12/25
3-Month
0.5100 +17.63%
on 12/22/25
1.4100 -57.45%
on 10/17/25
-0.2749 (-31.42%)
since 10/14/25
52-Week
0.5100 +17.63%
on 12/22/25
1.4100 -57.45%
on 10/17/25
-0.6701 (-52.76%)
since 01/14/25

Most Recent Stories

More News
XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

CALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Announces Closing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

CALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Initiates IND Preparation for XORLO™ in Gout Program

CALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Announces USD $3 Million Offering

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)
XORTX Provides Update on FDA Type B Meeting Request

XRTX.VN : 0.830 (+3.75%)
XRTX : 0.5999 (+0.82%)

Business Summary

XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta.

See More

Key Turning Points

3rd Resistance Point 0.6268
2nd Resistance Point 0.6134
1st Resistance Point 0.6042
Last Price 0.5999
1st Support Level 0.5816
2nd Support Level 0.5682
3rd Support Level 0.5590

See More

52-Week High 1.4100
Fibonacci 61.8% 1.0662
Fibonacci 50% 0.9600
Fibonacci 38.2% 0.8538
Last Price 0.5999
52-Week Low 0.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar